precision therapy

precision therapy

Radiation oncology Stereotactic therapy for treating CA, directing multiple beams of low-dose radiation intersecting at the tumor site, and high-dose radiation to the exact site, while not harming surrounding healthy tissue. See Radiation oncology.
References in periodicals archive ?
We are following their footsteps in seeking to make this novel precision therapy accessible to patients in Greater China as soon as possible.
According to the company, BLU-667 is an investigational, once-daily oral precision therapy specifically designed for highly potent and selective targeting of oncogenic RET alterations.
Repotrectinib is being developed as a precision therapy targeting ROS1 and NTRK-driven cancers.
Another cancer treatment from Bayer is the oral precision therapy Larotrectinib, which has been granted accelerated approval in November 2018 by the US FDA for the treatment of adult and pediatric patients with tropomyosin receptor kinase (TRK) fusion cancer.
Princess Haifa was speaking during the opening ceremony of the first international conference on "Advances in Breast Cancer Research: Towards Precision Therapy," organized by King Faisal Specialist Hospital and Research Center (KFSHRC) in Riyadh.
They also found that those who underwent precision therapy had about 7% lower healthcare related costs in the last three months of life as compared to those who underwent standard therapy.
Vascular BioSciences CEO and study co‒author David Mann, commented, "Endoarterial biopsy provides an innovative method to assess miRNA, gene, and other molecular regulation in normal and hypertensive pulmonary arteries at specific stages of the disease and opens a new window for precision therapy."
The next phase of cancer therapy, precision therapy, will leverage the ability to target specific molecular features to treat a cancer based on its characteristics rather than its tissue of origin alone.
"Just as precision therapy and immunotherapy are transforming cancer treatment, precision medicine and immunoprevention approaches are being translated to the clinic and showing great promise.
23 November 2012 - US precision therapy tools developer Volcano Corporation (NASDAQ:VOLC) said today it had sealed a definitive deal to acquire Israeli sector firm Sync-Rx Ltd for an unspecified amount.
"Diagnostic genetics testing holds great promise as a driver of precision therapy, but patent thickets and restrictive licensing arrangements threaten their delivery," said MPEG LA President and CEO Larry Horn.
Precision Therapy, pioneered in Sweden, offers targeted tumor control and can be used to combat some formerly untreatable cancers.
Full browser ?